Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Abbisko Cayman Limited ( (HK:2256) ) has shared an update.
Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has completed the first patient dosing in a registrational study of irpagratinib, a highly-selective FGFR4 inhibitor, for treating Hepatocellular Carcinoma (HCC). Irpagratinib, which received Breakthrough Therapy Designation from China’s National Medical Products Administration, is the first therapeutic agent to use molecularly defined biomarkers for precision-targeted HCC treatment. The study aims to evaluate the efficacy and safety of irpagratinib in patients with advanced or unresectable HCC exhibiting FGF19 overexpression, a biomarker linked to aggressive tumor biology. This development could position Abbisko as a leader in innovative HCC treatments, potentially impacting stakeholders by offering a novel therapeutic option for a challenging cancer type.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Therapeutics Co., Ltd., founded in April 2016 and based in Shanghai, is an oncology-focused biopharmaceutical company dedicated to discovering and developing innovative medicines to address unmet medical needs in China and globally. The company, established by experienced professionals from top multinational pharmaceutical companies, has developed a robust pipeline of programs centered on precision oncology and immuno-oncology.
Average Trading Volume: 5,699,242
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.96B
See more data about 2256 stock on TipRanks’ Stock Analysis page.